FOAmicus Therapeutics FOLD NASDAQ · Healthcare · United States
$14.49 +0.00% +$0.00
- Market cap
- $4.55B
- Enterprise value
- $4.78B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 7.2x
- P/FCF
- 469.5x
- EV/EBITDA
- 112.7x
- ROIC
- -645.7%
- Gross margin
- 88.5%
- Net margin
- -4.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 5.4x
- Beta
- 0.48
- Free float
- 99.2%
About the company
Amicus Therapeutics, Inc. is an American biotechnology company specializing in the development of innovative therapies for the treatment of rare genetic diseases, particularly lysosomal storage disorders. The company focuses on developing enzyme replacement therapies and other biologic treatments that can improve the health of patients suffering from diseases such as Fabry disease, Gaucher disease, and Pompe disease. Amicus Therapeutics is known for its advanced research in enzyme therapy and highly targeted treatment methods, offering new possibilities for patients for whom current treatments have been insufficiently effective.
Sector
Healthcare
Industry
Biotechnology
CEO
Bradley L. Campbell
Employees
499
Headquarters
Philadelphia
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 15% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: Operating profit does not even cover the interest on its debt.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
- What speaks for it: The price moves less than the market (beta 0.48).
Statements
Every number